Discovering new drugs, both our work & our passion

Ecrins Therapeutics is a clinical-stage privately held Biotech company specialized in the discovery and development of innovative oncology drugs. Using its original drug candidate discovery platform, Ecrins has created a pipeline of high-value projects. Our main drug candidate ET-D5 is being developed for human and veterinary oncology applications and is currently in the regulatory preclinical phase (human oncology). Validating our approach, ET-D5 is already being tested in the canine clinical trial of patients suffering from high-grade sarcomas. Several additional innovating drug discovery programs are progressing rapidly towards pre-clinical development; their targets are unique and will be used for the treatment of cancer.

About us

Who we are: our history, our team, our advisors
and our partners

R&D programs

Our Mission : to develop innovative therapies that bring new hope to patients.

Investors

Discover why investing in Ecrins Therapeutics is a great opportunity for you

News

Find our most recent news
right here

Contact us

Have a question? Looking for information?
Please, contact us.

Welcome to Ecrins Therapeutics

But why “Ecrins”?
Our work is like a long trek to a summit, in which teamwork and perserverence are the keys to reaching our goals.
The Ecrins national park is a gorgeous part of the French Alps in which each hike is a fantastique adventure in front of amazing landscapes. At Ecrins Therapeutics, we have the unique opportunity to work in Grenoble, a city at the foot of the Alps mountain range. None of us is insenstive to the beauty that surrounds us, especially our CEO and cofounder Andrei POPOV who enjoys hiking and rock climbing in the Ecrins National Park.